Steven Willey's questions to Compass Therapeutics Inc. (CMPX) leadership • Q2 2025
Question
An analyst on behalf of Steven Willey at Stifel asked about the patient demographics in the Tivesimig trial and the confidence that they reflect historical trial populations, given the lower-than-expected death rate. He also inquired about the preclinical safety data for CTX-10726.
Answer
CEO Thomas Schuetz responded that while it's hard to make cross-trial comparisons without the final data, the randomization was stratified by key prognostic variables (performance status, metastatic disease location, anatomic subtype), ensuring the treatment arms should be well-balanced. He confirmed that preclinical data for CTX-10726 will be presented at a scientific conference later in the year.